Eleven days after Cochrane said anti-amyloid Alzheimer's drugs show absent or trivial clinical effects, the most important response remains the one not given.

FDA has not publicly changed course. CMS has not publicly changed payment policy. Eisai and Lilly have not produced the kind of reimbursement-facing answer that would tell families, infusion centers and Medicare contractors how to reconcile a major evidence review with continuing public payment. The news is no longer just the review. It is the silence around the money.

The paper's Day 10 account of institutional silence while Medicare kept paying argued that silence had become policy. Day 11 confirms the pattern. A health system can disagree with a review. It cannot pretend a review of this size did not arrive.

The Cochrane review pooled 17 clinical trials with 20,342 participants and concluded that the effects of amyloid-beta-targeting monoclonal antibodies on cognition and dementia severity at 18 months were trivial, while functional gains were small at best. It also found increased risk of amyloid-related imaging abnormalities, including brain swelling and microbleeds. [1]

Scientific American summarized the finding in plain language: drugs once hailed as breakthroughs made no meaningful difference to disease progression and increased risks of brain bleeding and swelling. [1] Powers Health carried the public-facing version for patients, while HealthEd captured the expert backlash from clinicians who argue the review pooled old failures with newer agents and compressed a slowly progressive disease into an 18-month window. [2] [3]

That debate matters. Lecanemab and donanemab are not simply abstractions in a meta-analysis. They are scheduled infusions, MRI monitoring, transport burdens, family hope, and Medicare reimbursement. A small effect may be meaningful to some patients. A trivial population effect may still contain subgroups. Clinical medicine lives in such tension.

But reimbursement is not bedside tenderness. It is a public decision about evidence, cost and risk. When a gold-standard evidence group says the class does not produce clinically meaningful benefit, the payer cannot answer only through inertia. Silence tells clinicians to keep doing what they were doing. It tells families the controversy is academic. It tells manufacturers the payment channel remains open.

The divergence is painful because both sides are partly right. Mainstream health coverage is still adjudicating the science: endpoints, trial selection, time horizons, and whether the newer drugs should be judged separately. Health X is asking a cruder question: if the effect is absent or trivial, why is Medicare still paying as if the breakthrough frame survived?

Patients deserve more than a slogan in either direction. They deserve to know whether the system believes these drugs are modestly useful, provisionally reimbursable, or overvalued interventions with burdens that exceed benefits. That answer must come from institutions, not from comment threads.

Day 11 is therefore a silence story. Not because nobody spoke, but because the entities with payment power did not.

-- NORA WHITFIELD, Chicago